Galectin Therapeutics (GALT) Accumulated Expenses (2010 - 2026)

Galectin Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 39.29% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 39.29% YoY), while the FY2025 annual figure was $4.7 million, up 210.05% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $4.2 million, down from $4.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $10.9 million in Q2 2024, with the low at $386000.0 in Q1 2023.
• The 5-year median for Accumulated Expenses is $4.2 million (2026), against an average of $4.2 million.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses plunged 94.94% in 2023, then soared 2189.12% in 2024.
• Galectin Therapeutics' Accumulated Expenses stood at $973000.0 in 2022, then climbed by 16.03% to $1.1 million in 2023, then surged by 34.9% to $1.5 million in 2024, then surged by 210.05% to $4.7 million in 2025, then dropped by 11.35% to $4.2 million in 2026.
• Business Quant data shows GALT's Accumulated Expenses at $4.2 million in Q1 2026, $4.7 million in Q4 2025, and $1.1 million in Q3 2025.